当前位置：
X-MOL 学术
›
J. Med. Chem.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2018-04-23 00:00:00 , DOI: 10.1021/acs.jmedchem.7b01896 Kurt G. Pike 1 , Bernard Barlaam 1 , Elaine Cadogan 1 , Andrew Campbell 2 , Yingxue Chen 3 , Nicola Colclough 1 , Nichola L. Davies 1 , Camila de-Almeida 1 , Sebastien L. Degorce 1, 4 , Myriam Didelot 4 , Allan Dishington 5 , Richard Ducray 4 , Stephen T. Durant 1 , Lorraine A. Hassall 5 , Jane Holmes 5 , Gareth D. Hughes 1 , Philip A. MacFaul 5 , Keith R. Mulholland 6 , Thomas M. McGuire 1 , Gilles Ouvry 4 , Martin Pass 1 , Graeme Robb 1 , Natalie Stratton 7 , Zhenhua Wang 8 , Joanne Wilson 1 , Baochang Zhai 8 , Kang Zhao 8 , Nidal Al-Huniti 3
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2018-04-23 00:00:00 , DOI: 10.1021/acs.jmedchem.7b01896 Kurt G. Pike 1 , Bernard Barlaam 1 , Elaine Cadogan 1 , Andrew Campbell 2 , Yingxue Chen 3 , Nicola Colclough 1 , Nichola L. Davies 1 , Camila de-Almeida 1 , Sebastien L. Degorce 1, 4 , Myriam Didelot 4 , Allan Dishington 5 , Richard Ducray 4 , Stephen T. Durant 1 , Lorraine A. Hassall 5 , Jane Holmes 5 , Gareth D. Hughes 1 , Philip A. MacFaul 5 , Keith R. Mulholland 6 , Thomas M. McGuire 1 , Gilles Ouvry 4 , Martin Pass 1 , Graeme Robb 1 , Natalie Stratton 7 , Zhenhua Wang 8 , Joanne Wilson 1 , Baochang Zhai 8 , Kang Zhao 8 , Nidal Al-Huniti 3
Affiliation
|
ATM inhibitors, such as 7, have demonstrated the antitumor potential of ATM inhibition when combined with DNA double-strand break-inducing agents in mouse xenograft models. However, the properties of 7 result in a relatively high predicted clinically efficacious dose. In an attempt to minimize attrition during clinical development, we sought to identify ATM inhibitors with a low predicted clinical dose (<50 mg) and focused on strategies to increase both ATM potency and predicted human pharmacokinetic half-life (predominantly through the increase of volume of distribution). These efforts resulted in the discovery of 64 (AZD0156), an exceptionally potent and selective inhibitor of ATM based on an imidazo[4,5-c]quinolin-2-one core. 64 has good preclinical phamacokinetics, a low predicted clinical dose, and a high maximum absorbable dose. 64 has been shown to potentiate the efficacy of the approved drugs irinotecan and olaparib in disease relevant mouse models and is currently undergoing clinical evaluation with these agents.
中文翻译：
共济失调毛细血管扩张突变（ATM）激酶的有效，选择性和口服可用抑制剂的鉴定：AZD0156（8- {6- [3- [Dimethylaminopropoxy] pyridin-3-yl} -3-methyl-1 -（四氢-2 H-吡喃-4-基）-1,3-二氢-2 H-咪唑并[4,5- c ]喹啉-2-一）
当在小鼠异种移植模型中与DNA双链断裂诱导剂结合使用时，ATM抑制剂（例如7）已证明ATM抑制具有抗肿瘤潜力。然而，7的性质导致相对较高的预测临床有效剂量。为了最大程度地减少临床开发过程中的磨损，我们试图确定预测的临床剂量低（<50 mg）的ATM抑制剂，并着重于提高ATM效能和预测的人类药代动力学半衰期（主要是通过增加体积）的策略的分布）。这些努力导致发现了64（AZD0156），这是一种基于咪唑并[4,5 - c ]喹啉-2-酮核的ATM特异强效选择性抑制剂。64具有良好的临床前药代动力学，较低的预计临床剂量和较高的最大可吸收剂量。已显示64可以增强批准的药物伊立替康和olaparib在与疾病相关的小鼠模型中的功效，目前正在使用这些药物进行临床评估。
更新日期：2018-04-23
中文翻译：
共济失调毛细血管扩张突变（ATM）激酶的有效，选择性和口服可用抑制剂的鉴定：AZD0156（8- {6- [3- [Dimethylaminopropoxy] pyridin-3-yl} -3-methyl-1 -（四氢-2 H-吡喃-4-基）-1,3-二氢-2 H-咪唑并[4,5- c ]喹啉-2-一）
当在小鼠异种移植模型中与DNA双链断裂诱导剂结合使用时，ATM抑制剂（例如7）已证明ATM抑制具有抗肿瘤潜力。然而，7的性质导致相对较高的预测临床有效剂量。为了最大程度地减少临床开发过程中的磨损，我们试图确定预测的临床剂量低（<50 mg）的ATM抑制剂，并着重于提高ATM效能和预测的人类药代动力学半衰期（主要是通过增加体积）的策略的分布）。这些努力导致发现了64（AZD0156），这是一种基于咪唑并[4,5 - c ]喹啉-2-酮核的ATM特异强效选择性抑制剂。64具有良好的临床前药代动力学，较低的预计临床剂量和较高的最大可吸收剂量。已显示64可以增强批准的药物伊立替康和olaparib在与疾病相关的小鼠模型中的功效，目前正在使用这些药物进行临床评估。
京公网安备 11010802027423号